**BIG NEWS IN THE PHARMA WORLD!**
The United Kingdom is dominating the development of next-generation drugs, with a booming biotech industry leading the way. The trailblazing company Exscientia, based in Oxford, is at the forefront of using AI to accelerate the drug discovery process. Their cutting-edge technology can reduce the development time of a drug from four years to just 18 months and cut the number of experiments needed by a staggering 90%.
**NOVO NORDISK LEADS THE WAY**
Novo Nordisk, a pharmaceutical giant, is taking things to the next level with the establishment of a “digital innovation hub” for their newest treatments. Their pipeline includes a pill version of the highly sought-after weight-loss drug, Wegovy. In response to the increasing demand for obesity treatments, Novo Nordisk has seen a surge in market value, with investors scrambling to get in on the action of the potentially $90 billion weight-loss market in the coming years.
**BOLSTERING TREATMENT AVAILABILITY**
In the midst of this critical demand, Novo Nordisk is investing heavily in the expansion of its manufacturing facilities to ensure ample supply of weight-loss drug Wegovy and diabetes treatment Ozempic. The company has shown a 31% increase in operating profits for the first nine months of this year, indicating a strong future in the booming obesity treatments market.
Are you excited about the possibilities for next-generation drugs and treatments? What do you think about the revolutionary use of AI in drug discovery? Let us know in the comments!
IntelliPrompt curated this article: Read the full story at the original source by clicking here